Constant activity of glutamine synthetase after morphine administration versus proteomic results

Glutamine synthetase is a key enzyme which has a regulatory role in the brain glutamate pool. According to previously published proteomic analysis, it was shown that the expression level of this enzyme is affected by morphine administration. In our study, we examined the activity of glutamine synthetase in various structures of rat brain (cortex, striatum, hippocampus and spinal cord) that are biochemically and functionally involved in drug addiction and antinociception caused by morphine. We were not able to observe any significant changes in the enzyme activity between morphine-treated and control samples despite previously reported changes in the expression levels of this enzyme. These findings stressed the fact that changes observed in the expression of particular proteins during proteomic studies may not be correlated with its activity

Game Based Learning on Urban Sustainability: The "Sustain" Project

SUSTAIN is an ERASMUS+ project with an innovative perspective on urban sustainability. Its target is to promote the importance of sustainability on the everyday problems of the cities among the students of higher education, which are the policy makers of tomorrow and the ones that will shape the future. In order to achieve its goals, the research team will develop a course that will be based on an interactive game with an analytical style of education. This game will allow students to learn about transportation sustainability and societal metabolism through playing. In addition, the research team will develop small and illustrative simulation models, which will make the definitions more concrete and allow students to experiment in a consequence-free environment. It is a quite innovative and hybrid perspective way of learning, in the sense that it will combine game-based learning with a cognitive and analytical style of education

The web-based simulation and information service for multi-hazard impact chains. Design document.

The overall objective of the PARATUS project and the platform is the co-development of a web-based simulation and information service for first and second responders and other stakeholders to evaluate the impact chains of multi-hazard events with particular emphasis on cross-border and cascading impacts. This deliverable provides a first impression of the platform and its components. A central theme in the PARATUS project is the co-development of the tools with stakeholders. The central stakeholders within the four applications case studies are therefore full project partners. They will be directly involved in the development of the platform. We foresee that the PARATUS Platform will have two major blocks: an information service that provides static information (or regularly updated information) and simulation service, which is a dynamic component where stakeholders can interactively work with the tools in the platform. The PARATUS will further make sure that documentation (e.g., software accompanying documentation) is also publicly available via the project website1 and other trusted repositories. The deliverable 4.1 was submitted to the European Commission on 31/07/2023 and is waiting for approval by the Research Executive Agency. Therefore, this current version may not represent the final version of the deliverable

Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.

Multiple sclerosis (MS) is a life-long, potentially debilitating disease of the central nervous system (CNS). MS is considered to be an immune-mediated disease, and the presence of autoreactive peripheral lymphocytes in CNS compartments is believed to be critical in the process of demyelination and tissue damage in MS. Although MS is not currently a curable disease, several disease-modifying therapies (DMTs) are now available, or are in development. These DMTs are all thought to primarily suppress autoimmune activity within the CNS. Each therapy has its own mechanism of action (MoA) and, as a consequence, each has a different efficacy and safety profile. Neurologists can now select therapies on a more individual, patient-tailored basis, with the aim of maximizing potential for long-term efficacy without interruptions in treatment. The MoA and clinical profile of MS therapies are important considerations when making that choice or when switching therapies due to suboptimal disease response. This article therefore reviews the known and putative immunological MoAs alongside a summary of the clinical profile of therapies approved for relapsing forms of MS, and those in late-stage development, based on published data from pivotal randomized, controlled trials